Autor: Firma CatalYm

CatalYm Presents Expanded Clinical and New Preclinical Data from

1. März 20221. März 2022 Firma CatalYmForschung und Entwicklungbiomarker, cancer, cell, cells, clinical, ctl, Exploration, gdf, gdfather, monotherapy, patients, research, therapy, treatment, with

CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company’s lead product candidate, the GDF-15 neutralizing antibody Mehr

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

12. November 202112. November 2021 Firma CatalYmForschung und Entwicklungcancer, cell, cells, clinical, ctl, gdf, immunotherapy, medical, monotherapy, new, patients, strong, therapy, treatment, with

First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1 Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor microenvironment Preclinical in vivo study validates Mehr